- Nearly half of 100 vulnerable medicines have at least one key starting material sourced exclusively from one country, creating systemic single-point failure risk across multiple downstream manufacturers.
- Parenteral products dominate vulnerability (63%), reflecting complex manufacturing and thin inventories, with many drugs appearing stable at finished-dose while remaining structurally fragile upstream.
...[PharmExecutive]
